investors

Strength of Oncology Pipeline Touted at Merck’s First Investor Day in Five Years
Strength of Oncology Pipeline Touted at Merck’s First Investor Day in Five Years
BioSpace
Merck
Keytruda
investors
Flag link:
Investor day prep at Merck includes a new strategy to pick up the pace on M&A
Investor day prep at Merck includes a new strategy to pick up the pace on M&A
Endpoints
Merck
investors
Keytruda
cancer
M&A
Flag link:
Is CEO pay linked to drug prices? Curious investors failed their campaign to find out
Is CEO pay linked to drug prices? Curious investors failed their campaign to find out
Fierce Pharma
Big Pharma
investors
drug pricing
executive pay
Flag link:
Investors to AbbVie, J&J, Merck and more: Fork over info on pricing and executive pay
Investors to AbbVie, J&J, Merck and more: Fork over info on pricing and executive pay
Fierce Pharma
AbbVie
Celgene
JNJ
Merck
Pfizer
Vertex Pharmaceuticals
investors
executive pay
Flag link:
J&J, Merck and Pfizer spent tax savings on investor payouts, not R&D: Oxfam
J&J, Merck and Pfizer spent tax savings on investor payouts, not R&D: Oxfam
Fierce Pharma
taxes
tax cuts
investors
R&D
Merck
JNJ
Pfizer
Flag link:
Should Biogen Investors Be Extra Nervous Right Now?
Should Biogen Investors Be Extra Nervous Right Now?
Motley Fool
Biogen
Alzheimer's disease
ICER
investors
Spinraza
Flag link:
Allergan taps Celgene vet Hugin for M&A guidance, but proxy brawlers aren't impressed
Allergan taps Celgene vet Hugin for M&A guidance, but proxy brawlers aren't impressed
Fierce Pharma
Allergan
investors
M&A
Bob Hugin
Flag link:
Could proxy advisors sway investors to vote ‘no’ on BMS-Celgene merger?
Could proxy advisors sway investors to vote ‘no’ on BMS-Celgene merger?
Fierce Pharma
Bristol-Myers Squibb
Celgene
investors
M&A
Flag link:
Allergan investors, rooting for a breakup, cheer rapastinel's phase 3 flop
Allergan investors, rooting for a breakup, cheer rapastinel's phase 3 flop
Fierce Pharma
Allergan
investors
rapastinel
Flag link:
Biotech's big-bucks buybacks begin to burn
Biotech's big-bucks buybacks begin to burn
EP Vantage
investors
biotech
Big Biotech
stock buybacks
Flag link:
Clovis Oncology to Pay the SEC $20 Million for Misleading Investors
Clovis Oncology to Pay the SEC $20 Million for Misleading Investors
BioSpace
Clovis Oncology
SEC
investors
lung cancer
rociletinib
Flag link:
Theranos settles lawsuit from investors claiming they were defrauded
Theranos settles lawsuit from investors claiming they were defrauded
Marketwatch
Theranos
investors
Elizabeth Holmes
Flag link:
Watch out, Allergan. Activist investor David Tepper won approval to push a shake-up
Watch out, Allergan. Activist investor David Tepper won approval to push a shake-up
Fierce Pharma
investors
Allergan
David Tepper
FTC
Flag link:
How big is too big for a CEO bonus target? Annoyed Shire investors have some ideas
How big is too big for a CEO bonus target? Annoyed Shire investors have some ideas
Fierce Pharma
Shire
Pharma CEOs
executive pay
investors
Flemming Ornskov
Flag link:
Novartis investors demand action amid 'swamp' of bribery allegations in Greece
Novartis investors demand action amid 'swamp' of bribery allegations in Greece
Fierce Pharma
Novartis
investors
bribery
Greece
Flag link:
Sanofi investors hungry for drug progress and deal news
Sanofi investors hungry for drug progress and deal news
Reuters
Sanofi
investors
innovation
Flag link:
U.S. biotechs can’t shake October blues as investors await next moves
U.S. biotechs can’t shake October blues as investors await next moves
Globe and Mail, Canada
biotech
investors
Biogen
Gilead Sciences
Celgene
Flag link:
Allergan executives named in investor suit over alleged generics price fixing
Allergan executives named in investor suit over alleged generics price fixing
Fierce Pharma
Allergan
investors
generics
drug pricing
Flag link:
US Spinraza sales cause concern among Biogen investors
US Spinraza sales cause concern among Biogen investors
Biopharma Dive
Biogen
Spinraza
spinal muscular atrophy
investors
Flag link:
With just a little encouragement, biotech investors are ready to fall in love again
With just a little encouragement, biotech investors are ready to fall in love again
Endpoints
biotech
investors
AnaptysBio
Flag link:

Pages